Aurinia Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 5, 2021, reports the financial results for Aurinia Pharmaceuticals Inc. for the quarter ended June 30, 2021. The company is incorporated in Canada and its common shares trade on The Nasdaq Stock Market LLC under the symbol AUPH.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
This 8-K serves as a notification of the results announcement and does not contain management commentary, forward-looking guidance, risk factors, or descriptions of unusual items. The document explicitly states that the information furnished is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2021) for actual revenue, net loss, and cash position figures.
- Verify the specific drivers of financial performance for the quarter ended June 30, 2021, as they are not listed in the 8-K text.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the attached press release.
- Confirm the company's cash runway and liquidity status from the detailed financial statements referenced in the exhibit.